Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Combination With Standard Therapy in Recurrent High Grade Gliomas
NCT03122197Phase 1Recruiting
- Sponsor
- University of Cincinnati
- Start
- May 2017
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of letrozole in high-grade glioma (HGG) (3 arms), sponsored by University of Cincinnati. Primary endpoints: Area Under the Curve at 5 days and Progression-Free Survival at 6 months. Started May 2017; status: recruiting.
02
Drugs
letrozole
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03122197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122197.